A Wyss Institute-led collaboration has used the institute’s organ-on-a-chip technology to identify the antimalarial drug amodiaquine as a potent inhibitor of infection with SARS-CoV-2, the virus that causes COVID-19.

With a $16 million agreement from DARPA, Harvard’s Wyss Institute will use its technology to identify and test already FDA-approved drugs that may prevent or treat COVID-19 infection.